Welcome to our dedicated page for Onconetix SEC filings (Ticker: ONCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Onconetix, Inc. (Nasdaq: ONCO) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, offering a structured view of how this commercial-stage biotechnology company reports on its men’s health and oncology business. Onconetix’s filings span registration statements, current reports, and proxy materials, each providing different angles on its operations, capital structure, and governance.
Through registration statements on Form S‑1 and S‑1/A, Onconetix details equity financing arrangements such as PIPE transactions involving Series D and Series E convertible preferred stock and associated warrants, as well as an equity line of credit with Keystone Capital Partners. These documents describe the number of shares registered for resale, conversion and exercise prices, and the company’s status as a smaller reporting company and emerging growth company. They also explain the impact of the company’s 1‑for‑85 reverse stock split on share counts and per‑share data.
Current reports on Form 8‑K provide timely disclosure of material events, including PIPE financing closings, licensing agreements, promissory notes, Nasdaq listing notices, and strategic transactions. For example, 8‑K filings describe the terms of the Series D and Series E preferred stock and warrants, the licensing agreement between Proteomedix and Immunovia related to the PancreaSure pancreatic cancer test, and amendments and waivers associated with promissory notes tied to the ENTADFI asset acquisition.
The company’s definitive proxy statement on Schedule 14A outlines proposals for stockholder approval, such as director elections, ratification of the independent registered public accounting firm, and approvals required under Nasdaq rules for issuing common stock upon conversion of preferred stock and exercise of warrants. These materials also confirm the date and location of the annual meeting and summarize the board’s recommendations.
On Stock Titan, each new 10‑K, 10‑Q, 8‑K, S‑1, DEF 14A, or other filing is captured as it becomes available from EDGAR. AI-powered tools can be used to highlight key sections, such as risk factors, descriptions of Proclarix and ENTADFI, financing terms, and Nasdaq compliance disclosures. Users interested in insider activity can also review Form 4 filings, when available, to see reported transactions by directors and officers.
By using this page, investors and researchers can quickly locate Onconetix’s quarterly and annual reports, capital raising disclosures, and governance documents, and rely on AI summaries to interpret complex sections without reading every page of the underlying filings.
Onconetix, Inc. (ONCO) set its 2025 annual meeting. The meeting will be held at 10:00 a.m. Eastern Time on December 5, 2025 at Ellenoff Grossman & Schole LLP, 1345 6th Ave, New York, NY 10105.
Stockholder proposals under Rule 14a-8 must be received at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio by the close of business on November 10, 2025. Nominations for directors for inclusion in the proxy materials are due by the same deadline. To comply with the universal proxy rules, stockholders soliciting proxies for their own director nominees must provide the information required by Rule 14a-19 by November 10, 2025. A public announcement of any adjournment or postponement will not reopen or extend the Rule 14a-8 submission window.
Onconetix, Inc. called its annual meeting for December 5, 2025, 10:00 a.m. ET, in New York. Stockholders of record at the close of business on October 21, 2025 may vote. The Board unanimously recommends voting FOR all items: elect one director, approve the Series D PIPE Proposal, approve the Series E PIPE Proposal, ratify the auditor, and allow potential adjournment.
The Series D and Series E PIPE proposals seek approval under Nasdaq Rule 5635(a) because the securities issuable upon conversion or exercise would exceed 20% of the voting power and outstanding common stock at issuance. Until approval, conversions and exercises at certain adjusted prices are restricted, and limited warrant exercisability could affect cash proceeds. The director election is by plurality; other proposals require a majority of votes cast. Common shares outstanding were 1,555,010 as of October 21, 2025. Series C, D and E preferred shares are not entitled to vote on these matters.
Onconetix, Inc. filed an S-1 to register up to 5,100,000 shares of common stock for resale by Keystone Capital Partners under an equity line of credit (ELOC). The company is not selling shares in this prospectus and will not receive proceeds from the Selling Stockholder’s resales. Separately, Onconetix may sell shares to Keystone under the ELOC and may receive up to $25.0 million in aggregate gross proceeds, depending on drawdowns and pricing.
Through October 15, 2025, the company sold approximately 661,762 shares under the ELOC for aggregate proceeds of about $7.1 million. Shares outstanding were 1,555,010 as of October 15, 2025. The Nasdaq last reported sale price was $3.71 per share on October 14, 2025. The ELOC includes a 4.99% beneficial ownership cap for Keystone, and 30% of gross proceeds from ELOC sales must be applied toward redemption of Series C Preferred Stock.
Onconetix, Inc. filed a Form D for a Regulation D private offering reporting a $12,977,670 total offering, all of which has been sold with $0 remaining. The company identified its industry as Biotechnology, is organized in Delaware, and lists its principal office in Cincinnati, OH. The filing shows the offering relied on Rule 506(b) and reports the date of first sale as 2025-09-22. The issuer reports no revenues and selected the aggregate net asset value bracket indicating no net assets.
The offering included multiple security types — equity, debt, and options/warrants — and accepted investments from 11 investors with a stated minimum investment of $208,823. No sales commissions or finders' fees were paid, and the filing indicates $0 in proceeds used to pay officers, directors, or promoters (estimate). The Form D was signed by Karina Fedasz, Interim Chief Financial Officer, on 2025-10-07.
Onconetix, Inc. entered into a private investment in public equity (PIPE) financing with institutional investors, raising approximately $6.25 million through Series E convertible preferred stock and warrants. The company issued 7,813 shares of Series E preferred stock and Warrants to purchase 2,025,223 shares of common stock.
The Series E preferred stock has a Conversion Price of $3.8576 per share of common stock, subject to anti-dilution and variable-price adjustments, with a Floor Price of $0.7715. If certain Triggering Events occur, a Default Dividend of 15.0% per year accrues on the stated value and holders gain alternate conversion rights.
The Warrants are immediately exercisable at an initial exercise price of $3.8576 per share, include only downward price adjustments, and have a three-year term. Both the preferred shares and Warrants are subject to an ownership cap, generally limiting a holder’s beneficial ownership to 4.99%, adjustable up to 9.99% with notice.
Onconetix, Inc. filed a Form 8-K reporting several material corporate actions disclosed in press releases dated September 26, 2025. The filing references a PIPE Financing and Settlement Agreement and a separate press release announcing the Termination of Merger Agreement. It also lists transaction exhibits including a Certificate of Designations that authorizes Series D Preferred Stock, a Form of Warrant, and the PIPE Financing and Settlement Agreement as exhibits. The filing describes an Alternate Conversion Right that permits holders to convert Preferred Shares into Common Stock after certain triggering events and after the Stockholder Approval Date at specified alternate conversion prices. The document is signed by the company’s Interim Chief Executive Officer and Interim Chief Financial Officer.
Onconetix, Inc. filed a Form 8-K reporting a material event: the filing includes a License Agreement dated September 17, 2025 between Immunovia AB and Proteomedix AG, and an attached Press Release dated September 22, 2025. The 8-K cover page shows standard solicitation/communication checkboxes left unchecked and identifies Karina M. Fedasz as Interim Chief Executive Officer and Interim Chief Financial Officer signing the filing.
This filing discloses the existence and filing of the license agreement and press release but does not include the license terms, financial consideration, milestones, or other commercial details. Investors should note the counterparties and dates disclosed; the filing itself provides notice of the agreement rather than substantive commercial or financial metrics.
Onconetix, Inc. reported a series of waiver agreements with Veru, Inc. extending payment dates for promissory notes multiple times during 2025. The company and Veru executed waivers on March 31, April 23, June 30, July 31 and August 28, 2025, each extending the due dates for the April Veru Note and related Veru Notes, with the most recent extension moving the April Veru Note to September 19, 2025.
The filing also attaches new promissory notes dated August 28, 2025 with Keystone Capital Partners, LLC and KCP Fund I, LLC, plus a Second Amended and Restated Promissory Note and an August 28, 2025 waiver between Veru and the company as exhibits. The disclosures reference earlier forbearance and note documents filed in 2023 and 2024 for full terms.
Andrew Oakley, a non-employee director of Onconetix, Inc. (ONCO), reported changes to his restricted stock awards. A restricted stock award originally granted March 23, 2025 was modified on August 15, 2025 to change the vesting date from August 31, 2025 to August 31, 2026, contingent on continued service as a non-employee director. The filing shows an additional restricted stock award of 618 shares granted that vests August 31, 2026 under the issuer's 2022 Equity Incentive Plan. The amounts are presented on a post 1-for-85 reverse split basis effected June 13, 2025, and total beneficial ownership following the transactions is 638 shares.
Tarsh Simon, a non-employee director of Onconetix, Inc. (ONCO), reported changes to his restricted stock awards. An original restricted stock award granted September 26, 2024 was modified on August 15, 2025 to extend its vesting date from August 31, 2025 to August 31, 2026, conditional on continued service as a non-employee director. The issuer completed a 1-for-85 reverse stock split on June 13, 2025; all share amounts in this report are presented on a post-split basis. The reporting person was also granted a separate restricted stock award of 618 shares that will vest in full on August 31, 2026 if he continues to serve as a non-employee director. The Form 4 is signed by Simon Tarsh on August 19, 2025.